Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amorcyte, Inc.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
NeoStem, the New York-based cell therapy company, plans to raise $16.5 million through the sale of 13.8 million share-and-warrant units at $1.20 per unit, a considerable discount to the 18 July stock closing price of $1.32.
Stem cell specialist NeoStem has agreed to purchase Amorcyte, a cardiovascular stem cell therapy developer, a move which will give it access to the cardiovascular therapy market. Amorcyte's lead product, AMR-001, is about to start a Phase II trial in acute myocardial infarction (AMI).
Recent research advances and relaxation of government restrictions have opened the stem cell field to product possibilities. Companies developing these potentially revolutionary products must also come up with workable business models. In this issue we profile five emerging contenders: Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics.